Medpace Holdings, Inc. MEDP Endocrine — Revenue
Discontinued — last reported Q4 '18
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medpace Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Medpace Holdings, Inc.’s 10-K, filed February 26, 2019, on SEC EDGAR. View the filing →
Questions, answered.
- What does endocrine — revenue mean?
- Revenue earned from providing clinical trial services for endocrine-related drug development projects.
- How do you interpret endocrine — revenue?
- An increase indicates growing demand for the company's specialized endocrine research services and successful project execution within this therapeutic vertical. A decrease may signal a slowdown in client R&D spending or increased competition in the endocrine clinical trial market.
- How does endocrine — revenue compare across companies?
- Peers in the contract research organization (CRO) industry report similar therapeutic-specific revenue streams, which are typically benchmarked against overall R&D spending trends in the biotechnology sector.